Osteosarcoma

A review of diagnosis, management, and treatment strategies

David S. Geller, Richard Gorlick

Research output: Contribution to journalArticle

279 Citations (Scopus)

Abstract

Despite significant advancements in the diagnosis and treatment of osteosarcoma to date, overall survival has remained relatively constant for over 2 decades. The challenge in osteosarcoma stems from the extreme variability from one tumor to the next, making it unlikely that a single target approach would be able to address all or even a majority of patients. Awareness, education, and proper referral patterns serve to minimize avoidable errors in diagnosis and treatment. However, it is unlikely that these efforts alone will significantly improve survival outcomes. Modern multi-agent chemotherapy has resulted in the greatest improvement in overall survival to date, and it is very likely that future improvements in survival will arise from combination-targeted chemotherapy in addition to conventional treatment.

Original languageEnglish (US)
Pages (from-to)705-718
Number of pages14
JournalClinical Advances in Hematology and Oncology
Volume8
Issue number10
StatePublished - Oct 2010
Externally publishedYes

Fingerprint

Osteosarcoma
Survival
Therapeutics
Combination Drug Therapy
Referral and Consultation
Education
Drug Therapy
Neoplasms

Keywords

  • Osteogenic sarcoma
  • Osteosarcoma

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Osteosarcoma : A review of diagnosis, management, and treatment strategies. / Geller, David S.; Gorlick, Richard.

In: Clinical Advances in Hematology and Oncology, Vol. 8, No. 10, 10.2010, p. 705-718.

Research output: Contribution to journalArticle

@article{f6931f50673b4e4c8c5d58a314974521,
title = "Osteosarcoma: A review of diagnosis, management, and treatment strategies",
abstract = "Despite significant advancements in the diagnosis and treatment of osteosarcoma to date, overall survival has remained relatively constant for over 2 decades. The challenge in osteosarcoma stems from the extreme variability from one tumor to the next, making it unlikely that a single target approach would be able to address all or even a majority of patients. Awareness, education, and proper referral patterns serve to minimize avoidable errors in diagnosis and treatment. However, it is unlikely that these efforts alone will significantly improve survival outcomes. Modern multi-agent chemotherapy has resulted in the greatest improvement in overall survival to date, and it is very likely that future improvements in survival will arise from combination-targeted chemotherapy in addition to conventional treatment.",
keywords = "Osteogenic sarcoma, Osteosarcoma",
author = "Geller, {David S.} and Richard Gorlick",
year = "2010",
month = "10",
language = "English (US)",
volume = "8",
pages = "705--718",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "10",

}

TY - JOUR

T1 - Osteosarcoma

T2 - A review of diagnosis, management, and treatment strategies

AU - Geller, David S.

AU - Gorlick, Richard

PY - 2010/10

Y1 - 2010/10

N2 - Despite significant advancements in the diagnosis and treatment of osteosarcoma to date, overall survival has remained relatively constant for over 2 decades. The challenge in osteosarcoma stems from the extreme variability from one tumor to the next, making it unlikely that a single target approach would be able to address all or even a majority of patients. Awareness, education, and proper referral patterns serve to minimize avoidable errors in diagnosis and treatment. However, it is unlikely that these efforts alone will significantly improve survival outcomes. Modern multi-agent chemotherapy has resulted in the greatest improvement in overall survival to date, and it is very likely that future improvements in survival will arise from combination-targeted chemotherapy in addition to conventional treatment.

AB - Despite significant advancements in the diagnosis and treatment of osteosarcoma to date, overall survival has remained relatively constant for over 2 decades. The challenge in osteosarcoma stems from the extreme variability from one tumor to the next, making it unlikely that a single target approach would be able to address all or even a majority of patients. Awareness, education, and proper referral patterns serve to minimize avoidable errors in diagnosis and treatment. However, it is unlikely that these efforts alone will significantly improve survival outcomes. Modern multi-agent chemotherapy has resulted in the greatest improvement in overall survival to date, and it is very likely that future improvements in survival will arise from combination-targeted chemotherapy in addition to conventional treatment.

KW - Osteogenic sarcoma

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=78649944462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649944462&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 705

EP - 718

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 10

ER -